Case report of a patient with metastatic non-small cell lung cancer with positive ALK gene rearrangement treated in the first line with alectini
2020
Abstract
ALK gene rearrangement (anaplastic lymphoma kinase) is a genetic change in non-small cell lung cancer (NSCLC) that predicts the effectiveness of targeted ALK inhibitor therapy. Nowadays, we have three generations of ALK inhibitors.
Alectinib, the current standard for the first line treatment of ALK positive NSCLC, is a highly selective and potent inhibitor of ALK and RET tyrosine kinase and since 1st November 2019 is reimbursed in the Czech Republic as the first line treatment of ALK + NSCLC.